SAB Biotherapeutics (SABS) Stock Price, News & Analysis

Company Overview

SAB Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing antibody-based medicines for infectious diseases, immune disorders and other serious health conditions. The company’s approach is designed to produce fully human polyclonal antibodies that can recognize and neutralize multiple targets associated with a disease.

SAB’s technology platform, known as DiversitAb, uses genetically engineered cattle with human immune-system components to generate human antibodies. The resulting antibody preparations are intended to support the development of therapeutics and potentially other medical products. The company has conducted development work on candidates including SAB-185, an antibody therapy investigated for COVID-19, and SAB-176, an influenza-focused therapeutic.

Founded in 2014, SAB Biotherapeutics is headquartered in Sioux Falls, South Dakota. The company became publicly traded on Nasdaq in 2021 following a business combination with Big Cypress Acquisition Corp. Its work has primarily centered on developing therapies for markets in the United States, with research and clinical activities conducted in collaboration with academic, government and industry partners.

Key Stats

• Today's Range: $2.62 to $2.88
• 50-Day Range: $2.68 to $3.93
• 52-Week Range: $2.10 to $5.15
• Volume: 892,782 shs
• Average Volume: 752,771 shs
• Market Capitalization: $243.85 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Moderate Buy

SAB Biotherapeutics Stock Analysis - MarketRank™

SAB Biotherapeutics scored higher than 45% of companies evaluated by MarketBeat, and ranked 597th out of 877 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.6 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

SAB Biotherapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.73, and is based on no strong buy ratings, 9 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

SAB Biotherapeutics has a consensus price target of $12.00, representing about 347.8% upside from its current price of $2.68.

Amount of Analyst Coverage

SAB Biotherapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for SAB Biotherapeutics are expected to grow in the coming year, from ($1.17) to ($0.79) per share.

Price to Book Value per Share Ratio

SAB Biotherapeutics has a P/B Ratio of 0.84. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 1.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

5.09% of the float of SAB Biotherapeutics has been sold short.

Short Interest Ratio / Days to Cover

SAB Biotherapeutics has a short interest ratio ("days to cover") of 4.99.

Change versus previous month

Short interest in SAB Biotherapeutics has recently increased by 19.10%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

SAB Biotherapeutics does not currently pay a dividend.

Dividend Growth

SAB Biotherapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.61

News Sentiment

SAB Biotherapeutics has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 4 news articles for SAB Biotherapeutics this week, compared to 2 articles on an average week.

MarketBeat Follows

2 people have added SAB Biotherapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.4 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, SAB Biotherapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

7.39% of the stock of SAB Biotherapeutics is held by insiders.

Percentage Held by Institutions

7.82% of the stock of SAB Biotherapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/06/2026
• Today: 10/14/2026
• Next Earnings (Estimated): 11/13/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:SABS
• CIK: 1833214
• Web: www.sab.bio
• Phone: (305) 845-2813
• Fax: N/A
• Employees: 86
• Year Founded: 2014

Price Target and Rating

• Average Price Target for SAB Biotherapeutics: $12.00
• High Price Target: $16.00
• Low Price Target: $7.00
• Potential Upside/Downside: +347.8%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.73
• Research Coverage: 11 Analysts

Profitability

• EPS (Trailing Twelve Months): ($1.30)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $13.27 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -6.74%
• Return on Assets: -6.06%

Debt

• Debt-to-Equity Ratio: 0.01
• Current Ratio: 9.22
• Quick Ratio: 9.22

Sales & Book Value

• Annual Sales: $1.32 million
• Price / Sales: 184.74
• Cash Flow: $0.32 per share
• Price / Cash Flow: 8.28
• Book Value: $3.18 per share
• Price / Book: 0.84

Miscellaneous

• Outstanding Shares: 90,990,000
• Free Float: 84,262,000
• Market Cap: $243.85 million
• Optionable: Not Optionable
• Beta: 0.58